chemotherapy（pemetrexed+CISPLATIN）

PreclinicalSmall molecule

chemotherapy（pemetrexed+CISPLATIN） is one of 49 small molecule programs targeting Lung Adenocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung AdenocarcinomaActive, not recruiting

Lung AdenocarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Lung Adenocarcinoma

#DrugCompanyPhaseTrials

Iressa

AstraZeneca

Phase 3

7 2

Keytruda

Merck & Co.

Phase 3

4 3

Lorbrena

Pfizer

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

7 5

Navelbine

PPierre Fabre Medicament

Phase 3

2 6

Sutent

Pfizer

Phase 2

2 7

Tagrisso

AstraZeneca

Phase 2

2 8

Nexavar

Bayer

Phase 2

1 9

Neulasta

Amgen

Phase 2

1 10

Beyfortus

BeiGene

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lung Adenocarcinoma1 trial

Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma

Unknown status·TThird Military Medical University·N/A·NCT02951897·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for chemotherapy（pemetrexed+CISPLATIN）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chemotherapy（pemetrexed+CISPLATIN） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chemotherapy（pemetrexed+CISPLATIN）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Third Military Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThird Military Medical University

chemotherapy（pemetrexed+CISPLATIN）

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lung Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News